Diagnostic performance of plasma p-Tau217, p-Tau181, and p-Tau231 across the Alzheimer’s disease continuum: a network meta-analysis
Xiaofen Chen, Tingting Huang, Chao Shi, Shuizhi Xu, Shuwei Fan · 2026
Read Diagnostic performance of plasma p-Tau217, p-Tau181, and p-Tau231 across the Alzheimer’s disease continuum: a network meta-analysis by Xiaofen Chen, Tingting Huang, Chao Shi, Shuizhi Xu, Shuwei Fan (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13272307.txt.
Description
Xiaofen Chen and coauthors compare in 2026 blood tests for Alzheimer's disease based on three forms of the tau protein. Blood markers promise cheaper, gentler diagnosis than spinal fluid or brain scans, yet which tau form and which lab platform work best at each disease stage was unsettled. The team pooled accuracy data across studies without double counting shared cohorts.
Eighteen studies covering 4,736 participants entered the network comparison. The tau217 form measured by mass spectrometry ranked highest for detecting amyloid pathology, with related tau217 measures next. Standard tau181 immunoassays ranked far lower. The ordering gives clinics firmer ground for choosing a blood test.
Catalog record
| CREATOR | Xiaofen Chen, Tingting Huang, Chao Shi, Shuizhi Xu, Shuwei Fan |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 26 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |